Skip to main content
SpringerLink
Log in

Fluoxetine Ameliorates the Aggravation of UC Symptoms in C57BL/6 Mice Induced by CUMS

  • Original Article
  • Published:
Current Medical Science Aims and scope Submit manuscript

Abstract

Objective

Patients with chronic ulcerative colitis (UC) often have mental symptoms such as depression and anxiety, and stress can lead to gastrointestinal diseases. However, the correlation between mental stress and UC is unclear. In this paper, chronic unpredictable mild stress (CUMS) was utilized to evaluate the involvement of mental factors in the pathogenesis of UC.

Methods

The CUMS model was used to evaluate the direct/indirect involvement of mental factors in the pathogenesis of UC. The behavior was evaluated by the open field, forced swimming, and tail suspension tests. Body weight, the disease activity index (DAI) score, colon length, and HE staining of colon tissue were used to evaluate the action of CUMS and fluoxetine.

Results

The results showed that weight loss and the DAI score increased in CUMS mice, but they had no meaningful effect on colon length and morphological structure of colon tissue. However, CUMS aggravated dextran sulfate sodium (DSS)-induced colon length shortening and colon morphological structure damage. Fluoxetine significantly improved the DAI score, shortened colon length, and damaged morphology and structure of the colons induced by CUMS combined with DSS in mice. Fluoxetine also decreased the level of IL-6 in the serum and the TNF-α and IFN-γ levels of colon tissue. Fluoxetine simultaneously improved behavioral abnormalities induced by CUMS combined with DSS in mice.

Conclusion

CUMS aggravated the UC symptoms induced by DSS, and fluoxetine could improve the UC symptoms due to its improvement in the inflammatory level and behavioral abnormalities.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Feuerstein JD, Moss AC, Farraye FA. Ulcerative Colitis. Mayo Clin Proc, 2019,94(7):1357–1373

    Article  PubMed  Google Scholar 

  2. Du L, Ha C. Epidemiology and Pathogenesis of Ulcerative Colitis. Gastroenterol Clin North Am, 2020,49(4):643–654

    Article  PubMed  Google Scholar 

  3. Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet, 2017,389(10080):1756–1770

    Article  PubMed  Google Scholar 

  4. Carvello M, Watfah J, Spinelli A. The Management of the Hospitalized Ulcerative Colitis Patient, the Medical-Surgical Conundrum. Curr Gastroenterol Rep, 2021,23(12):25

    Article  PubMed  Google Scholar 

  5. Kózka M, Skowron W, Bodys-Cupak I. Determinants of the level of anxiety and fears in a group of patients with ulcerative colitis. Ann Agric Environ Med, 2019,26(2):337–340

    Article  PubMed  Google Scholar 

  6. Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol, 2019,114(3):384–413

    Article  PubMed  Google Scholar 

  7. Raine T, Bonovas S, Burisch J, et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. J Crohns Colitis, 2022,16(1):2–17

    Article  PubMed  Google Scholar 

  8. Domínguez Jiménez JL, Pelado García EM, Copado Herrera R. Mesalazine-induced acute hepatitis. Gastroenterol Hepatol, 2015,38(4):302–303

    Article  PubMed  Google Scholar 

  9. Kotlyar DS, Lewis JD, Beaugerie L, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol, 2015,13(5):847–858

    Article  CAS  PubMed  Google Scholar 

  10. Atreya R, Neurath MF, Siegmund B. Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF? Front Med, 2020,7:517

    Article  Google Scholar 

  11. Tavakoli P, Vollmer-Conna U, Hadzi-Pavlovic D, et al. A Review of Inflammatory Bowel Disease: A Model of Microbial, Immune and Neuropsychological Integration. Public Health Rev, 2021,42:1603990

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Yuan X, Chen B. Depression and anxiety in patients with active ulcerative colitis: crosstalk of gut microbiota, metabolomics and proteomics. Gut Microbes, 2021,13(1):1987779

    Article  PubMed  PubMed Central  Google Scholar 

  13. Gao X, Tang Y, Lei N, et al. Symptoms of anxiety/depression is associated with more aggressive inflammatory bowel disease. Sci Rep, 2021,11(1):1440

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Vicentini FA, Szamosi JC, Rossi L, et al. Colitis-associated microbiota drives changes in behaviour in male mice in the absence of inflammation. Brain, Behav, and Immun, 2022,102:266–278

    Article  CAS  Google Scholar 

  15. Yousefi-Manesh H, Dejban P, Mumtaz F, et al. Risperidone attenuates acetic acid-induced colitis in rats through inhibition of TLR4/NF-kB signaling pathway. Immunopharmacol Immunotoxicol, 2020,42(5):464–472

    Article  CAS  PubMed  Google Scholar 

  16. Minaiyan M, Hajhashemi V, Rabbani M, et al. Evaluation of anti-colitic effect of fluvoxamine against acetic acid-induced colitis in normal and reserpinized depressed rats. Eur J Pharmacol, 2015,746:293–300

    Article  CAS  PubMed  Google Scholar 

  17. Li N, Lu Y. Forty Cases of Adjuvant Therapy for Elderly Patients with Ulcerative Colitis Assciated with Anxiety /Depression by Paroxetine Hydrochloride. Herald of Medicine (Chinese), 2015,34(7):903–906

    Google Scholar 

  18. Zhou Y, Wu J. Efficacy of sertraline hydrochloride in the treatment of ulcerative colitis with depression. Chinese Journal of Digestion (Chinese), 2015,35(9):595–598

    CAS  Google Scholar 

  19. Yang Z. Clinical effect of Deanxit combined with mesalazine in the treatment of ulcerative colitis. Mod Diagn Treat (Chinese), 2013,24(17):3920–3920

    Google Scholar 

  20. Shi X. Clinical efficacy of sertraline hydrochloride combined with mesalazine in the treatment of ulcerative colitis with depression. Chin J Clin Rational Drug Use (Chinese), 2016,9(23):46–47

    Google Scholar 

  21. Zhang Z, Yang L, Wang B, et al. Protective role of liriodendrin in mice with dextran sulphate sodium-induced ulcerative colitis. Int Immunopharmacol, 2017,52:203–210

    Article  CAS  PubMed  Google Scholar 

  22. Li Y, Adam R, Colombel JF, et al. A characterization of proinflammatory cytokines in dextran sulfate sodium-induced chronic relapsing colitis mice model. Int Immunopharmacol, 2018,60:194–201

    Article  CAS  PubMed  Google Scholar 

  23. Sun L, Zhang H, Cao Y, et al. Fluoxetine ameliorates dysbiosis in a depression model induced by chronic unpredicted mild stress in mice. Int J Med Sci, 2019,16(9):1260–1270

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Wu H, Wang R, Qin X, et al. Effects of chronic stress on depressive-like behaviors and JMJD3 expression in the prefrontal cortex and hippocampus of C57BL/6 and ob/ob mice. J Psychiatr Res, 2021,133:142–155

    Article  PubMed  Google Scholar 

  25. Archer J. Tests for emotionality in rats and mice: a review. Anim Behav, 1973,21(2):205–235

    Article  CAS  PubMed  Google Scholar 

  26. Bourin M, Mocaër E, Porsolt R. Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. J Psychiatry Neurosci, 2004,29(2):126–133

    PubMed  PubMed Central  Google Scholar 

  27. Antoniuk S, Bijata M, Ponimaskin E, et al. Chronic unpredictable mild stress for modeling depression in rodents: Meta-analysis of model reliability. Neurosci Biobehav Rev, 2019,99:101–116

    Article  PubMed  Google Scholar 

  28. Marcinkute M, Afshinjavid S, Fatokun AA, et al. Fluoxetine selectively induces p53-independent apoptosis in human colorectal cancer cells. Eur J Pharmacol, 2019,857:172441

    Article  CAS  PubMed  Google Scholar 

  29. Tatiya-Aphiradee N, Chatuphonprasert W, Jarukamjorn K. Immune response and inflammatory pathway of ulcerative colitis. J Basic Clin Physiol Pharmacol, 2018,30(1):1–10

    Article  PubMed  Google Scholar 

  30. Zhu L, Gu P, Shen H. Protective effects of berberine hydrochloride on DSS-induced ulcerative colitis in rats. Int Immunopharmacol, 2019,68:242–251

    Article  CAS  PubMed  Google Scholar 

  31. Barberio B, Zamani M, Black CJ, et al. Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol, 2021,6(5):359–370

    Article  PubMed  Google Scholar 

  32. Li K, Yan L, Zhang Y, et al. Seahorse treatment improves depression-like behavior in mice exposed to CUMS through reducing inflammation/oxidants and restoring neurotransmitter and neurotrophin function. J Ethnopharmacol, 2020,250:112487

    Article  CAS  PubMed  Google Scholar 

  33. Ford AC, Sperber AD, M. Corsetti, et al. Irritable bowel syndrome. Lancet, 2020,396(10263):1675–1688

    Article  CAS  PubMed  Google Scholar 

  34. Xu H, Cai F, Li P, et al. Characterization and Analysis of the Temporal and Spatial Dynamic of Several Enteritis Modeling Methodologies. Front Immunol, 2021,12:727664

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Zhao J, Li C, Jing X, et al. Corylin ameliorates chronic ulcerative colitis via regulating the gut-brain axis and promoting 5-hydroxytryptophan production in the colon. Phytomedicine, 2023,110:154651

    Article  Google Scholar 

  36. Samantha D, Idalia G, Fabiola T, et al. Interplay between Serotonin, Immune Response, and Intestinal Dysbiosis in Inflammatory Bowel Disease. Int J Mol Sci, 2022,23(24):15632

    Article  Google Scholar 

  37. Yu F, Huang S, Zhang H, et al. Comparison of 5-hydroxytryptophan signaling pathway characteristics in diarrhea-predominant irritable bowel syndrome and ulcerative colitis. World J Gastroenterol, 2016,22(12):3451–3459

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Author notes

  1. The authors contributed equally to this work.

Authors and Affiliations

  1. Jiangxi Province Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science and Technology Normal University, Nanchang, 330013, China

    Teng Zhao, Yu-xin Zhou, Rong-jie Wang, Ying Li, Liang-liang Zhou & Zhen-hua Chen

  2. Department of Liver Disease, The Ninth Hospital of Nanchang, Nanchang, 330006, China

    Ping Wan

Authors
  1. Teng Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yu-xin Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rong-jie Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ping Wan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ying Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Liang-liang Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Zhen-hua Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Liang-liang Zhou or Zhen-hua Chen.

Ethics declarations

The authors declare no conflicts of interest.

Additional information

This project was supported by grants from the National Natural Science Foundation Youth Project of China (No. 81703716), Jiangxi Science Foundation for Distinguished Young Scholars (No. 20224ACB216019), the Natural Science Foundation of Jiangxi Province (No. 20202BABL206151 and No. 20202BABL216026), Youth Talents Project of Jiangxi Science and Technology Normal University (No. 2017QNBJRC006), Doctoral Startup Fund of Jiangxi Science and Technology Normal University (No. 2019BSQD015), Department Education Science and Technology Research Project of Jiangxi (No. GJJ201134), the Open Project of Jiangxi Provincial Key Laboratory of Drug Design and Evaluation (No. JKD-KF-2104), and the National Undergraduate Training Program for Innovation of China (No. 202211318024).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhao, T., Zhou, Yx., Wang, Rj. et al. Fluoxetine Ameliorates the Aggravation of UC Symptoms in C57BL/6 Mice Induced by CUMS. CURR MED SCI 43, 1033–1042 (2023). https://doi.org/10.1007/s11596-023-2743-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11596-023-2743-4

Key words

Search

Navigation